1. Home
  2. STAA vs MPLT Comparison

STAA vs MPLT Comparison

Compare STAA & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$29.00

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$29.83

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAA
MPLT
Founded
1982
2018
Country
United States
United States
Employees
N/A
133
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
STAA
MPLT
Price
$29.00
$29.83
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
$22.81
$32.67
AVG Volume (30 Days)
640.9K
268.8K
Earning Date
05-12-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$239,442,000.00
N/A
Revenue This Year
$30.82
N/A
Revenue Next Year
$8.41
N/A
P/E Ratio
$288.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.59
$12.24
52 Week High
$35.87
$33.28

Technical Indicators

Market Signals
Indicator
STAA
MPLT
Relative Strength Index (RSI) 50.23 50.79
Support Level $28.03 $26.07
Resistance Level $31.05 $31.69
Average True Range (ATR) 1.00 2.49
MACD -0.28 -0.11
Stochastic Oscillator 36.09 56.23

Price Performance

Historical Comparison
STAA
MPLT

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: